Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Orbimed Advisors Llc Insider Profile
32 Followers
Orbimed Advisors Llc, Shareholder at CTI BioPharma, holds 3.41M shares in NeuroPace (Ticker: NPCE), holds 0.00 shares in Kinnate Biopharma (Ticker: KNTE), holds 0.00 shares in Theseus Pharmaceuticals (Ticker: THRX). Most recently, Orbimed Advisors Llc Sold ― shares of NeuroPace on May 03, 2024 for an estimated value of 409.43K.
Profitable Transactions
108 out of 197 Profitable Transactions
Average Return
+4.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of Orbimed Advisors Llc's holdings
Insider Roles
Roles that Orbimed Advisors Llc holds in companies
Most Profitable Insider Trade
The most profitable trade made by Orbimed Advisors Llc
Orbimed Advisors Llc's Trading History
CTI BioPharma
Jan 11, 2021
―
Informative Sell
7.00M
$68.36M
Intercept Pharma
Jul 21, 2015
―
Uninformative Buy
―
$21.29M
Repare Therapeutics
Sep 08, 2021
Shareholder
Uninformative Sell
274.79K
$11.46M
Acutus Medical
Jul 21, 2021
Director, Ten Percent Owner
Informative Buy
15.00M
$68.94K
CalciMedica
Sep 29, 2020
Ten Percent Owner
Uninformative Buy
―
$23.31M
PMV Pharmaceuticals
Nov 24, 2023
Ten Percent Owner
Informative Sell
195.76K
$13.21M
Prelude Therapeutics
May 24, 2023
Director, Ten Percent Owner
Informative Buy
5.00M
$39.71M
Galecto
Aug 17, 2023
Ten Percent Owner
Informative Sell
617.01K
$1.03M
Kinnate Biopharma
Apr 05, 2024
―
Uninformative Sell
―
$0.00
Terns Pharmaceuticals
Dec 28, 2022
Director, Ten Percent Owner
Informative Buy
1000.00K
$42.36M
Decibel Therapeutics
Feb 19, 2021
―
Uninformative Buy
―
$4.34M
Edgewise Therapeutics
Jan 25, 2024
Director, Ten Percent Owner
Informative Buy
5.00M
$270.48M
Ikena Oncology
Sep 14, 2023
Director
Uninformative Buy
―
$10.23M
NeuroPace
May 03, 2024
Ten Percent Owner
Informative Sell
409.43K
$28.95M
Janux Therapeutics Inc
Dec 30, 2021
Director
Informative Sell
820.12K
$11.31M
Theseus Pharmaceuticals
Feb 14, 2024
―
Uninformative Sell
―
$0.00
Compass Therapeutics
Nov 10, 2022
Director, Ten Percent Owner
Informative Buy
1.29M
$30.07M
Third Harmonic Bio, Inc.
Sep 21, 2022
Director, Ten Percent Owner
Uninformative Buy
―
$68.77M
Verona Pharma
May 15, 2023
Director
Informative Sell
9.94M
$56.10M
Disc Medicine
Dec 20, 2023
Director
Informative Sell
102.13K
$51.68M
Turnstone Biologics Corp.
Jul 24, 2023
Director, Ten Percent Owner
Informative Buy
5.00M
$9.45M
ARS Pharmaceuticals
Aug 31, 2023
Director
Informative Buy
3.10M
$80.77M
ArriVent BioPharma, Inc.
Jan 31, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$26.79M
X4 Pharmaceuticals
Nov 20, 2017
Ten Percent Owner
Informative Buy
3.66M
$1.96M
scPharmaceuticals
Nov 29, 2022
Ten Percent Owner
Informative Buy
4.00M
$24.91M
Pieris Pharmaceuticals
May 02, 2018
See Remarks, Ten Percent Owner
Informative Sell
6.35M
$433.40K
Kala Pharmaceuticals
Feb 12, 2018
Ten Percent Owner
Informative Buy
323.25K
$23.79M
Synlogic
Apr 22, 2021
Director
Uninformative Buy
5.00M
$6.62M
Armo Biosciences Inc
Jun 22, 2018
―
Uninformative Sell
205.95M
$205.86M
Adicet Bio
Jan 26, 2024
Director, Ten Percent Owner
Informative Buy
7.50M
$4.31M
Audentes Therapeutics
Mar 12, 2018
―
Informative Sell
5.47M
$212.29M
Corvus Pharmaceuticals
Sep 22, 2021
Director, Ten Percent Owner
Informative Sell
6.76M
$14.44M
Rhythm Pharmaceuticals
May 24, 2018
See Remarks, Ten Percent Owner
Informative Sell
595.77K
$107.64M
Aadi Bioscience
Jul 02, 2018
Director, Ten Percent Owner
Informative Buy
2.99M
$9.25M
Constellation Pharmaceuticals
Jul 24, 2018
―
Uninformative Buy
―
$14.21M
Xtant Medical Holdings
Aug 17, 2022
Director, Ten Percent Owner
Uninformative Buy
―
$174.49K
Principia Biopharma
May 22, 2019
―
Informative Sell
30.25M
$160.65M
Guardant Health
Oct 11, 2018
Ten Percent Owner
Uninformative Buy
―
$200.70K
Logicbio Therapeutics
Oct 25, 2018
―
Uninformative Buy
―
$13.39M
Inspire Medical Systems
Aug 19, 2020
Director
Informative Sell
14.93M
$299.41K
Thoratec Corp
Dec 13, 2018
―
Uninformative Buy
―
$337.59M
Alector
Apr 16, 2020
Ten Percent Owner
Informative Sell
2.01M
$10.01M
Avedro
Feb 19, 2019
―
Uninformative Buy
―
$97.48M
Tricida
Nov 25, 2022
―
Informative Sell
2.21M
$0.00
Turning Point Therapeutics
Apr 24, 2019
―
Uninformative Buy
―
$154.11M
NextCure
May 13, 2019
Director, Ten Percent Owner
Informative Buy
5.25M
$4.47M
TELA Bio
Apr 21, 2023
Ten Percent Owner
Informative Sell
1.79M
$16.36M
89bio
Jan 27, 2022
Ten Percent Owner
Informative Sell
592.38K
$15.93M
Springworks Therapeutics
Sep 14, 2022
Ten Percent Owner
Informative Sell
4.92M
$228.98M
Prevail Therapeutics
Jun 26, 2019
―
Uninformative Buy
―
$317.92M
Alpine Immune Sciences
Jan 16, 2024
Director
Informative Buy
1.85M
$174.07M
Sierra Oncology
Jul 01, 2022
―
Uninformative Sell
108.06M
$0.00
Arcutis Biotherapeutics
Jun 28, 2022
Ten Percent Owner
Informative Sell
7.29M
$3.25M
Passage Bio
Jun 29, 2023
Ten Percent Owner
Informative Buy
1.00M
$11.81M
Enliven Therapeutics
May 19, 2023
Director, Ten Percent Owner
Informative Buy
9.10K
$209.73M
Keros Therapeutics
Apr 13, 2020
Director
Uninformative Buy
―
$60.77M
Oric Pharmaceuticals
Mar 31, 2021
Director
Uninformative Sell
2.43M
$19.89M
Adaptimmune Therapeutics
Jun 06, 2018
Director
Informative Sell
253.63K
$5.49M
Viewray
Aug 20, 2018
Ten Percent Owner
Informative Sell
5.19M
$835.40
Glaukos
Mar 06, 2018
Director
Informative Sell
26.79M
$0.00
Steadymed
Sep 07, 2018
―
Informative Sell
18.94M
$0.00
Nabriva Therapeutics
Dec 30, 2016
Director, Ten Percent Owner
Informative Buy
―
$50.95K
Spyre Therapeutics
Feb 21, 2017
Ten Percent Owner
Informative Buy
563.88K
$54.27M
Relypsa Inc
Jul 26, 2016
―
Informative Sell
129.39M
$236.73M
Mirati Therapeutics
Feb 05, 2015
―
Informative Buy
2.00M
$74.37M
Sientra
Oct 13, 2015
Ten Percent Owner
Informative Sell
1.72M
$513.00
Pacira Pharmaceuticals
Mar 13, 2012
Ten Percent Owner
Informative Sell
1.11M
$71.96M
Anthera Pharmaceuticals
Feb 01, 2013
Director
Informative Buy
3.76M
$223.86K
Otonomy
Nov 30, 2015
―
Informative Sell
1.94M
$212.76K
Insulet
―
Director
―
$260.27M
NxStage Medical
Dec 13, 2010
―
Informative Sell
53.25K
$80.71M
Loxo Oncology
Dec 12, 2017
―
Informative Sell
20.63M
$220.82M
Acceleron Pharma
Sep 26, 2013
―
Uninformative Buy
―
$103.12M
Supernus Pharmaceuticals
Feb 14, 2013
Ten Percent Owner
Informative Sell
2.28M
$23.66M
ChemoCentryx
Feb 15, 2012
―
Uninformative Buy
―
$47.23M
Albireo Pharma
Jun 11, 2009
―
Uninformative Sell
―
$65.60M
Sorrento Tech Inc
Oct 05, 2017
―
Informative Sell
137.10K
$19.75K
Athersys
Apr 29, 2011
Ten Percent Owner
Informative Sell
551.98K
$152.50
Amarin
Sep 05, 2012
Director
Uninformative Sell
3.37M
$4.86K
Avanir Pharmaceuticals
―
―
―
―
Complete Genomics
―
―
―
―
Given Imaging Ltd
―
―
―
―
Volcano Corp
―
―
―
―
Ambit
May 24, 2013
―
Informative Buy
233.37K
―
List of latest transactions for each holding click on a transaction to see Orbimed Advisors Llc's performance on stock
You May Also Like
Orbimed Advisors Llc insider profile FAQ
What is the percentage of profitable transactions made by Orbimed Advisors Llc?
The percentage of profitable transactions made by Orbimed Advisors Llc is 55%.
What is the average return per transaction made by Orbimed Advisors Llc?
The average return per transaction made by Orbimed Advisors Llc is 4.40%.
What stocks does Orbimed Advisors Llc hold?
Orbimed Advisors Llc holds: CTIC, ICPT, RPTX, AFIB, CALC, PMVP, PRLD, GLTO, KNTE, TERN, DBTX, EWTX, IKNA, NPCE, JANX, THRX, CMPX, THRD, VRNA, IRON, TSBX, SPRY, AVBP, XFOR, SCPH, PIRS, KALA, SYBX, ARMO, ACET, ~BOLD, CRVS, RYTM, AADI, CNST, XTNT, PRNB, GH, LOGC, INSP, ~THOR, ALEC, ~AVDR, TCDAQ, TPTX, NXTC, TELA, ETNB, SWTX, PRVL, ALPN, SRRA, ARQT, PASG, ELVN, KROS, ORIC, ADAP, VRAYQ, GKOS, STDY, NBRVF, SYRE, RLYP, MRTX, SIENQ, PCRX, ANTH, OTIC, PODD, NXTM, LOXO, XLRN, SUPN, CCXI, ALBO, ROKA, ATHXQ, AMRN, AVNR, ~GNOM, GIVN, VOLC, ~AMBI stocks.
What was Orbimed Advisors Llc’s latest transaction?
Orbimed Advisors Llc latest transaction was an Informative Sell of $409.43K.
What was Orbimed Advisors Llc's most profitable transaction?
Orbimed Advisors Llc’s most profitable transaction was an Informative Buy of SIENQ stock on October 28, 2014. The return on the trade was 570.60%.
What is Orbimed Advisors Llc's role in CTI BioPharma?
Orbimed Advisors Llc's role in CTI BioPharma is Shareholder.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.